Literature DB >> 11457536

Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants.

K Peter1, Y Men, G Pantaleo, B Gander, G Corradin.   

Abstract

The goal of this study was the induction of a strong CTL response against multiple CTL epitopes present in HIV proteins using short synthetic peptides. Four HLA-A2.1 restricted peptides (RT 476-484, p17 77-85, gp41 814-823, RT 956-964) that showed stable binding to the HLA-A2.1 molecule in an in vitro binding assay were able to elicit a strong specific immune response in HLA-A2.1 transgenic mice when injected with IFA or Montanide. The use of biodegradable microspheres (MS) as adjuvant was also successfully tested for all peptides. When the peptides were injected as a mixture the response was weaker as compared to individual injections of the peptides indicating the occurrence of immunodominance (ID). We are currently investigating whether ID can be overcome by a combined injection of peptide loaded MS with different release patterns. Taken together, it seems feasible to induce a specific CTL response in HLA-A2.1 transgenic mice against several HIV proteins using short synthetic peptides and human compatible adjuvants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457536     DOI: 10.1016/s0264-410x(01)00179-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

2.  Biodegradable particles as vaccine delivery systems: size matters.

Authors:  Vijaya B Joshi; Sean M Geary; Aliasger K Salem
Journal:  AAPS J       Date:  2012-10-10       Impact factor: 4.009

3.  Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages.

Authors:  Lars Thiele; Hans P Merkle; Elke Walter
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

4.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.

Authors:  Stacey L Demento; Stephanie C Eisenbarth; Harald G Foellmer; Craig Platt; Michael J Caplan; W Mark Saltzman; Ira Mellman; Michel Ledizet; Erol Fikrig; Richard A Flavell; Tarek M Fahmy
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

5.  A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.

Authors:  Ali Azizi; Susan Aucoin; Helina Tadesse; Rita Frost; Masoud Ghorbani; Catalina Soare; Turaya Naas; Francisco Diaz-Mitoma
Journal:  Genet Vaccines Ther       Date:  2005-08-22

6.  Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.

Authors:  Braeden Donaldson; Farah Al-Barwani; Simon J Pelham; Katie Young; Vernon K Ward; Sarah L Young
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

7.  Overlapping synthetic peptides as vaccines.

Authors:  Shisong Jiang; Ruijiang Song; Sergei Popov; Saied Mirshahidi; Ruth M Ruprecht
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

8.  A novel polyepitope vaccine elicited HIV peptide specific CD4+ T cell responses in HLA-A2/DRB1 transgenic mice.

Authors:  Haitao Liu; Wei Shen; Jiayi Shu; Zhihua Kou; Xia Jin
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.